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1. Summary 
The Iberian lynx (Lynx pardinus) is considered the most endangered felid species in the 
world, less than 250 animals left. The narrow genetic basis may contribute to render this 
species particularly susceptible to infectious diseases. Within a six-month period 
starting in December 2006, a feline leukemia virus (FeLV) outbreak of surprising 
virulence killed about 60% of infected animals. Sequencing of the FeLV envelope 
surface unit gene revealed a common origin in all lynxes. The sequences were closely 
related to FeLV-A/61E, originally isolated from a cat in Colorado (1, 2) and only mildly 
pathogenic in domestic cats. Nevertheless, a particular virulence of the FeLV strain 
found in Iberian lynxes could not be ruled out. In order to evaluate the virulence of the 
lynx FeLV, we assessed the disease-inducing potential of the Iberian lynx`s FeLV strain 
in its probable original host, the domestic cat. Intraperitoneal inoculation of specified 
pathogen-free (SPF) domestic cats with FeLV-infected Iberian lynx blood did not lead to 
a particularly severe outcome. Thus, the FeLV epidemic in the Iberian lynxes seems to 
be more related to a potential primary immunodeficiency of these animals than to an 
extremely virulent FeLV strain. 
 
2. Introduction 
The Iberian lynx (Lynx pardinus) is the most endangered felid in the world. Not more 
than 200-250 animals remain, confined in two isolated populations in southern Spain, in 
the Doñana National Park and Sierra Morena, respectively (3, 4). The genetic diversity 
in the Iberian lynxes is very low, especially in the Doñana population (5), and may 
contribute to render this endangered species particularly susceptible to pathogens and 
possibly even to opportunistic infectious agents. In late 2006, an outbreak of feline 
leukemia virus (FeLV) killed 6 out of 10 viremic animals within a six-month period (6). 
FeLV is a gammaretrovirus naturally occurring worldwide in domestic cats and some 
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small felids (7, 8). Four subtypes of FeLV are known, FeLV-A, -B, -C and -T (9-13). 
While FeLV-A is present in all FeLV-infected cats, FeLV-B arises by recombination 
between exogenous FeLV-A and endogenous FeLV-related sequences. FeLV-C and 
FeLV-T occur through mutation of FeLV-A and can cause pure red cell aplasia or fatal 
immunodeficiency syndrome, respectively. Infection usually occurs through the oronasal 
route with an initial replication in lymphoid tissues of the oropharynx, followed by 
replication in rapidly dividing cells across the body. Once the bone marrow is infected, 
the virus replicates extensively and viremia develops which in turn affect further organs 
and tissues of the body (14, 15). Four different outcomes of the infection are known: 
abortive (no virus detected in blood after exposure, with or without bone marrow 
infection (16)), regressive, progressive, and the rarely focal or atypical infection (no 
viremia, virus replication only in defined tissues) (17-22). The majority of cats exposed 
to FeLV develop regressive infection (with or without viremia) characterized by the 
elimination of the virus from blood (although proviral DNA remains detectable (19, 23)) 
and production of neutralizing antibodies through effective immune response (7, 24, 25). 
Latency, for example in the bone marrow can persist for years (7, 26), while the cats 
stay healthy but the virus can be occasionally reactivated through immunosupression 
(27). Progressively infected cats shed the virus continuously, they can live 
asymptomatic for up to 2-3 years but usually succumb to FeLV-associated diseases 
such as for example immunosupression, degenerative disorders of the hematopoietic 
system (e.g., anemia) or neoplastic diseases (e.g., lymphomas or leukemia) (28-31). 
The course of infection is influenced by host and viral factors (e.g., virus subtype), co-
infections and/or stress (7, 17, 22, 32-35). Resistance to persistent viremia increases 
with age (36). There is still no curative therapy for FeLV but effective vaccines are 
available which protect against persistent viremia and virus spread within a population 
(37-41). 
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The dramatic infection outcome in Iberian lynxes was rather unexpected, since in 
persistently viremic, experimentally FeLV-infected domestic cats the six-months survival 
rate is of about 90% and the mean survival time of FeLV-positive field domestic cats is 
about one year (42). In addition, the rare FeLV infections in the Iberian lynxes detected 
before 2006 did not lead to severe outbreaks (6, 43, 44), probably because of the 
solitary lifestyle of these felids. Studies in several populations of wildcats from Europe 
and the Middle East have shown a relatively high prevalence of FeLV antigenemia (8, 
45-47), and at least another FeLV outbreak has been characterized in the Florida puma 
(48). Although, these FeLV infections do not appear to have the same dramatic 
consequences as the one seen in the Iberian lynxes in 2006/ 2007. Furthermore, the 
highly pathogenic FeLV-C or FeLV-A variant strains like 61C (which causes together 
with strain 61E the Feline acquired immune deficiency syndrome (FAIDS) (49)) were not 
present in the FeLV-positive Iberian lynxes (6). Another atypical hallmark of the FeLV 
outbreak was the clear association with hemotropic mycoplasmas infection (6), while 
recent studies in domestic cats failed to detect this relationship (50, 51). So far, it is not 
clear if this association is linked to host genetics (i.e., a general immune system 
dysfunction of the Iberian lynxes) or to a peculiar characteristic of the infecting virus 
strain that may have rendered the host more susceptible to specific pathogens. 
To avoid the spread of FeLV, in 2007 progressively infected lynxes were removed from 
the field, the non-infected animals were vaccinated against FeLV, and the management 
practices changed in order to reduce intra-specific contact and contact between lynxes 
and domestic cats (e.g., modification of feeding stations, cat removal) (52, 53). So far, 
these measures have been successful: since 2007 the only new case had been from a 
mother-to-child transmission in late 2009 (Guillermo López, personal communication). 
Nevertheless, the potential pathogenicity of the FeLV strain carried by the Iberian lynxes 
cannot be neglected: retransmission from Iberian lynxes to domestic cats of a 
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particularly virulent FeLV strain may have profound consequences, as seen for cross-
species transmission in other species (53-59). Thus, to assess the disease-inducing 
potential of the lynx`s FeLV in domestic cats, twelve three-month old specific pathogen-
free (SPF) domestic cats were inoculated with either blood from a FeLV-viremic Iberian 
lynx, or with blood from a FeLV-free Iberian lynx mixed with FeLV-A/Glasgow-1 strain; 
or with the FeLV-A/Glasgow-1 strain alone. The course of infection followed until five 
months post-infection (p.i.). 
 
3. Materials and methods 
3.1. Animals 
Sixteen 8-week-old SPF male, domestic kittens (Liberty Research Inc., Waverly, NY, 
USA) were included in this study. The cats were divided into four groups of four cats 
each and housed in separate rooms under barrier conditions. Each cat was clinically 
examined after receipt from the breeder. Blood and serum samples, oropharyngeal, 
ocular and rectal swabs were collected to verify their SPF and health status. The blood 
was analyzed for hematological and clinical-biochemical abnormalities and tested by 
real-time TaqMan PCR or real-time reverse transcriptase (RT)-PCR for the presence of 
known feline pathogens (6, 60-68). At the arrival in our facility, all cats were negative for 
FeLV and feline immunodeficiency virus (FIV) provirus, feline parvo- (FPV), calici- 
(FCV), and coronavirus (FCoV); Bartonella henselae and the three feline hemotropic 
mycoplasmas (Mycoplasma haemofelis (Mhf), Candidatus Mycoplasma haemominutum 
(CMhm), Candidatus Mycoplasma turicensis (CMt)). Conjunctival swabs tested negative 
for FCV, feline herpesvirus-1 (FHV1) and Chlamydophila felis, the oropharyngeal swabs 
negative for FCV and FHV1, and all rectal swabs for FCoV and FPV. EDTA serum was 
negative for FeLV p27 antigen and for antibodies against FCoV, FCV, FHV1, FPV, and 
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FIV (21, 69, 70). In addition, the cats were blood typed (ID- Gel Test Feline A+B Typing; 
DiaMed AG, Cressier sur Morat, Switzerland). 
3.2. Experimental design and infection 
All cats were infected intraperitoneally at the age of 12 weeks. All inocula were thawed 
at 37°C and stored on ice until use. Animals of group 1 were inoculated with 1ml of 
EDTA blood in 20% Dimethyl sulfoxide (DMSO, Sigma-Aldrich, Buchs, Switzerland) 
from a viremic two-year old male Iberian lynx from the Los Villares rescue center in 
Spain (Doñana area, Coto del Rey subpopulation), which survived the outbreak in 2006/ 
2007. The blood was stored at room temperature during shipment from Spain to 
Switzerland (24hrs) and preserved in 20% DMSO after receipt, packed on ice for two 
hours, stored at -80°C for two days and finally transferred into liquid nitrogen for long-
term storing. The blood was positive for FeLV (p27 60% of the laboratories control, 9.8 x 
107 copies virus/ml) and for CMhm (6.9 x 105 copies/ml). Animals of group 2 were 
inoculated with 1ml EDTA blood in 20% DMSO from a free-ranging female Iberian lynx 
of the same area as the one used for group 1. The blood was shipped at the same time 
as group 1 blood, and was positive by PCR for CMhm only (3.7 x 105 copies/ml). In 
addition, the cats of group 2 were inoculated with 0.2ml FeLV-A/Glasgow-1 strain 
(500’000 focus-forming units (FFU), p27 195% of the laboratories control, 1.35 x 1010 
virus copies/ml) (71). Animals of group 3 were infected with 0.2ml FeLV-A/Glasgow-1 
strain (500’000 FFU) in 20% DMSO and 0.6ml RPMI Medium (Invitrogen AG, Basel, 
Switzerland), and finally animals of group 4 inoculated with 1ml RPMI Medium 
(Invitrogen AG) in 20% DMSO. Animals of this latter group served as age-matched 
negative control. Blood samples from the two lynxes were of the same type (A) as the 
SPF cats. All cats were monitored daily for signs of illness after virus inoculation; body 
temperature and weight were recorded at each sampling day. To avoid unwanted 
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effects from cryptic infections from the lynx blood, a thoroughly health check was 
performed again at week 16p.i. as described above (3.1). 
3.3. Sample collection and processing 
EDTA blood samples were collected under light anesthesia (3mg/kg S-Ketamin (Keta-
S®; Dr. E. Graeub AG, Bern, Switzerland), 5μg/kg Medetomidin (Dorbene®; Dr. E. 
Graeub AG), and 0.2mg/kg Butorphanol (Morphasol-4®; Dr. E. Graeub AG), 
administrated intramuscularly) at the time point of infection (week 0), and at week 1-6, 
8, 10, 13, 16, and 20p.i.. EDTA-anticoagulated plasma was recovered from blood after 
centrifugation for 10min at 3’000rpm in a table-top centrifuge. All samples were 
immediately frozen at -80°C until they were processed. 
3.4. Hematology 
Hemograms were performed using a Sysmex XT-2000iV (Sysmex Corporation, Kobe, 
Japan) (72). Packed cell volume (PCV) values between 33% and 45% (5% and 95% 
quantiles) and leucocytes between 4’600/μl and 12’800/μl (5% and 95% quantiles) were 
considered to be within the reference range. Diff-Quick-stained (Medion Diagnostics, 
Dudingen, Switzerland) smears were evaluated by light microscopy for leukocyte 
differentiation. 
3.5. Detection and quantification of FeLV proviral and plasma viral RNA loads 
and of Candidatus Mycoplasma haemominutum (CMhm) by real-time PCR 
and RT-PCR 
Total nucleic acids (TNA) were extracted from an EDTA-anticoagulated blood volume 
containing 106 leucocytes, or from a maximum volume of 100μl, using the MagNA Pure 
LC Total Nucleid Acid Isolation Kit (Roche diagnostics AG, Rotkreuz, Switzerland). Cell 
copy numbers, FeLV proviral DNA quantities and CMhm loads were determined by real-
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time PCR as described (60-62). For detection of FeLV viral RNA in plasma, TNA were 
extracted from 200μl EDTA plasma using the MagNA Pure LC Total Nucleic Isolation 
Kit (Roche) and quantified by real-time RT-PCR as described (60). 
3.6. Detection of FeLV p27 antigen and FeLV antibodies by ELISA and Western 
Blot 
FeLV viremia was determined by p27 double antibody sandwich ELISA as described 
(73). Results were calculated as the percentage of a positive control (culture 
supernatant of FL-74 feline lymphoblastoid cell line permanently infected with FeLV), 
which was assayed with every plate. Values above 4% were considered to be positive. 
In agreement with the European Pharmacopoeia (2005), a cat was designated 
progressively infected when FeLV p27 antigen was positive for three consecutive weeks 
or on five occasions between weeks 3 and 15p.i.. Anti-FeLV whole virus antibodies 
were determined by ELISA using 100ng of gradient purified FL-74 FeLV with a dilution 
of 1:100 as described (74). Values above 25% of a SPF-serum pool were considered to 
be positive. In addition, FeLV antibodies were detected by Western blot in week 0 and 
20p.i. as described, using serum obtained from a pool of immune cats and a mixture of 
monoclonal antibodies against p27, p15E and gp70 as a positive control (75) (+Ref: 
siehe Andrea Major Paper Ref. Nr. 26 und 30, ref 28 ist deine #75). 
3.7. FeLV subtyping 
Two microliters of blood TNA extracts of all cats from week 20p.i. (except Q1 and Q2 
which had to be sacrificed for humane reasons at week 10, respectively 13p.i.), and 
from the FeLV viremic lynx used for the transmission experiment, were analyzed by 
conventional PCR for presence of FeLV-A, -B and -C using previously described 
primers (table 1) (76, 77). Each reaction contained a final concentration of 500nM of 
each primer with 0.4µl 10mM dNTP, 4µl 5x Phusion HF Buffer, 0.2µl Phusion Taq 
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Polymerase (2U/µl, Finnzymes, Keilaranta, Finnlad) in a final volume of 20µl, and was 
amplified on a Biometra gradient cycler (Labrepco, Horsham PA, USA) under following 
conditions: initial denaturation of 2min at 98°C followed by 40 cycles of 98°C for 20sec, 
52°C (FeLV-C) or 64°C (FeLV-A/-B) for 30sec and 72°C for 80sec with a final 
elongation step of 72°C for 10min. PCR products were visualized by agarose gel 
electrophoresis. 
Table 1
Name 
. FeLV subtyping primers. 
5’-3’ sequence Length (bases) Product length (bases) 
FeA-F RB59 CAATGTAAAACACGGGGCAC 20  
1071 
FeA-R RB17 TAGTGATATTGGTTCTCTTCG 21 
FeB-F RB53 ACAACGGGAGCTAGTG 16  
857 
FeB-R RB17 TAGTGATATTGGTTCTCTTCG 21 
FeC-F RB58 AGATCTTGGGCACGTTATTCC 21  
1754 
FeC-R RB47 TTGTGAAATGGCATTGCTGC 20 
 
3.8.  FeLV virus titers 
Tissue Culture Infectious Dose 50 (TCID50) was calculated using five-fold serial 
dilutions of the viruses. Six wells of a 24-well-plate with each 10’000 QN10 cells per 
dilution were incubated with 250µl virus dilute in cell culture medium (78) for 2 hours at 
37°C, the inoculum washed away and the cells cultured further in 400µl medium for 8 
days with addition of 400µl medium after 4 days. Presence of infectious virus was 
determined by p27 ELISA as described (74), and TCID50 was calculated using the 
Karber formula (79). 
3.9. Statistics  
Statistical analyses were conducted using GraphPad software version 5.00 (GraphPad 
Software Inc. La Jolla, CA, USA). Longitudinal effects on FeLV viral, FeLV proviral and 
CMhm loads of the different groups were compared to each other using two-way 
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repeated measures ANOVA with Bonferroni post-test. Outcomes between groups were 
compared using Fisher’s exact test. P-values < 0.05 were considered to be statistically 
significant. 
 
4. Results 
4.1. Pathogen detection in Iberian lynx blood 
The obtained lynx blood was PCR/RT-PCR negative for all tested feline pathogens 
except FeLV (p27 60%, provirus 9 x 106 copies/ml blood, viral RNA 9.8 x 107 copies/ml 
plasma, titer of approximately 2’000 FFU/ml estimated by TCID50 comparison with the 
Glasgow-1 stock virus used for group 2 and 3 infection), and CMhm (6.9 x 105 
copies/ml) - lynx blood used for group 1; or CMhm (3.7 x 105 copies/ml) alone - lynx 
blood used for group 2. The lynx plasma used to infect cats of group 1 was seropositive 
for FCV (1:320), whereas no antibodies were found to all other tested pathogens. 
4.2. Outcome of FeLV infection 
4.2.1. FeLV DNA, RNA and p27 antigen detection, subtyping 
According to the results obtained from p27 ELISA, the four cats of groups 2 and 3, and 
two of group 1 (P2, Q2) developed a progressive infection. Two cats from group 1 (S1, 
R3) were regressively infected (figure 1a). All cats infected became FeLV provirus and 
viral RNA positive, indicating that FeLV infection had occurred in all of them (figure 1b 
and c). FeLV-B was detected in one cat (R1, group 3) at euthanasia five months post-
infection, all others were positive for FeLV-A subtype alone. All cats of group 4 were 
negative for all tests throughout the experiment. 
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(a) 
 
(b) 
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(c) 
 
Fig.1 FeLV antigen p27 (a), proviral (b), and plasma viral RNA (c) loads during the course of 
experimental FeLV-A infection. The dotted/broken line in (a) represents the threshold for p27 
positive results (≥ 4% of the positive control). Group 1: cats Q2, P2, R3, S1. Group 2: cats Q1, 
M2, N2, R2. Group 3: cats Q3, R1, M3, S3. Data points for cats Q1 and Q2 are missing starting 
from week 13 and 16p.i., respectively because the cats had to be sacrificed for humane 
reasons. There was no statistical difference in the outcomes (regressive vs progressive) 
between the different groups. FeLV p27, viral and proviral loads were not statistically different 
between the groups. 
 
4.2.2. Humoral immune response 
Seroconversion to FeLV was found in all cats except in those of the negative control 
group. The cats turned positive starting at week 1-2 after infection. Three group 1 cats 
(P2, R3, S1) showed a high humoral immune response against FeLV until the end of 
the experiment, while only two out of seven progressively infected cats (M3, S3) were 
still positive for FeLV whole virus antibodies (figure 2). 
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Fig.2 FeLV whole virus (FL-74) antibodies recorded during the study against weeks post 
infection. The dotted/broken line represents the threshold for positive results (≥ 25% of the 
positive control). Group 1: cats Q2, P2, R3, S1. Group 2: cats Q1, M2, N2, R2. Group 3: cats 
Q3, R1, M3, S3. Group 4: cats Q4, N1, P1, S2. Data points for cats Q1 and Q2 are missing 
starting from week 13 and 16p.i., respectively because the cats had to be sacrificed for humane 
reasons. 
 
Antibodies levels to FeLV varied significantly over time between the groups (p=0.0017). 
The difference was caused mainly by group 1 starting from week 8 (pBonferroni<0.001 for 
weeks 8 to 20p.i.). Serum of four infected cats was Western blot positive at week 20p.i. 
(figure 3). The regressively infected cats R3 and S1 were positive for p58, p27 and 
p15E, cat P2 weakly for p58 and strongly for p15E. Cat Q1 was weakly positive at week 
10p.i. for P15E. 
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Fig.3 FeLV Western blot analysis of 1:100 diluted plasma samples (diluted 1:100) from week 0 
(prior to challenge) and week 20p.i. of the 16 experimentally infected SPF cats. Data for cats Q1 
and Q2 are of week 10 and 13 p.i., respectively because the cats had to be sacrificed for 
humane reasons. The positions of FeLV p15E (two bands), p27, p58 and gp70 are highlighted 
(open arrows). Positive controls: serum obtained from a pool of immune cats (pos. contr.) and 
mixture of monoclonal antibodies against FeLV gp70, p27, p15E and respectively 
(Gp70,p27,p15E mAB). 
 
4.3. Outcome of CMhm infection  
All cats were hemoplasma PCR negative at week 0p.i.. While all four cats of group 2 
became positive by week 1p.i., three cats of group 1 were positive starting at week 1, 3 
and 6p.i. (figure 4a and b). One cat (Q2) never became positive in blood during the 
whole experiment. No significant difference in copy numbers was found after week 6p.i. 
between the groups. However, the overall course of CMhm infection was significantly 
different between the two groups (p=0.0319), especially in weeks 4 and 5 (pBonferroni < 
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0.01). Clinical signs of CMhm infection were absent in the recipient cats. Anemia was 
observed in one cat Q2 (group 1), in which the PCV dropped from 25% to 18%, 
however this cat was never positive for CMhm in blood. 
 
(a)  
 
(b)  
Fig.4 Time course of CMhm loads in experimentally infected SPF cats. Group 1 (a) and group 2 
(b) loads are expressed as 45 minus the cycle threshold (Ct) values measured. Data points for 
cats Q1 and Q2 are missing starting from week 13 and 16p.i., respectively because the cats had 
to be sacrificed for humane reasons. 
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4.4. Hematology and clinical disease 
All cats and lynxes were blood type A. The cats showed some fluctuation in mean PCV 
values during infection but values remained within the reference range throughout the 
study. PCV and white blood cells showed no significant change between groups. Two 
cats had to be euthanatized during the experiment. Cat Q1 (group 2) developed a fatal 
panleukopenia at week 10p.i., while cat Q2 (group 1) developed skin lesions on the 
back, head and neck during week 8 to 10p.i., and later on an edema in the belly. At 
week 13p.i. the PCV declined from 25% to 18%, with a low total protein of 32.8g/l, and 
albumin of 11.6g/l, and an increased lipase 558 U/L and amylase of 2’241 U/L. In 
autopsy, next to the distinct edema, a middle-grade acute pancreatitis and omentitis 
was found. 
4.5. Post-infection health test 
At week 16p.i. a second health test was performed to rule out the influence of cryptic 
infections in the lynx blood. Indeed, cat P2 (group 1) was found to be seropositive for 
FCV (titer 1:160) and FHV1 (titer of 1:320). Conjunctiva and saliva swabs extracted and 
tested by RT-/PCR were negative at this time point. Tests of all earlier time points 
revealed that this cat became FHV1 PCR positive only once in blood in week 1p.i. (Ct 
36.9), where it was weakly seropositive (titer of 1:20) as well. FHV1, serology was 
positive at weeks 10 and 13p.i. (titer of 1:40 and 1:160) as well, FCV serology positive 
first at week 13p.i. (titer of 1:80). 
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5. Discussion 
The aim of this study was to assess the pathogenic potential of the FeLV strain 
circulating among Iberian lynxes in 2006/2007 outbreak in case of possible 
retransmission to resident domestic cats. We therefore obtained EDTA-blood from a 
viremic Iberian lynx that was infected in 2006 and held in the Los Villares Rescue 
Center in Spain since then. Because no FeLV-infected Iberian lynx is free of co-infection 
with hemotropic mycoplasmas (6), FeLV-free Iberian lynx blood, which was also co-
infected with the same mycoplasma strain (CMhm), had to be obtained as matched 
control. In addition to the determination of cross-transmission potential of FeLV from 
Iberian lynxes to domestic cats, this is, to our knowledge, the first report of successful 
hemotropic mycoplasmas infection transmission after 24h storage of the blood at room 
temperature followed by cryopreservation. To rule out possible influences of CMhm co-
infection in the pathogenesis of FeLV infection, SPF domestic cats were infected either 
with the FeLV-A/Glasgow-1 strain alone (group 3) or with FeLV-A/Glasgow-1 and the 
CMhm-positive blood (group 2). The course of infection in these two groups was 
identical. All developed a progressive FeLV infection and in only one cat (group 3) the 
more pathogenic FeLV-B strain was observed, while all cats were negative for FeLV-C. 
The course of CMhm infection was identical in all cats of group 2, with a bacteremia 
peak during weeks 4 to 5. One cat from group 2 (Q1) developed a fatal panleukopenia, 
at week 10p.i. which may have been caused through FeLV replication in the bone 
marrow. FeLV-induced panleukopenia has been recognized for many years (7, 22). 
Thus, an eventual contribution to increased pathogenicity of FeLV from intrinsic factors 
present in the Iberian lynx blood can be excluded.  
Two of the cats (S1, R3) from group 1 (infected with FeLV-positive Iberian lynx blood) 
were regressively infected and two (Q2, P2) progressively infected according to p27 
ELISA outcomes. Because of the small group size, the outcome was not statistically 
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different from the other two groups. Nevertheless, whole virus antibodies levels were 
significantly different towards the end of the experiment and Western blot analyses 
suggested that a third cat from group 1 (P2) may have become regressively infected as 
well. 
This outcome can be seen as in accordance with the low titer of the virus used for 
infection (about 1’000 times lower than the Glasgow-1 stock), which may have 
hampered the establishment of an effective progressive infection. However, in group 1 
no difference from known FeLV infection outcomes was observed. Although the cause 
of disease in cat Q2 is still unclear, biopsy of a skin lesion (neck) was positive for FeLV 
sequences and FeLV antigens as demonstrated by RT-PCR and immunohistology, 
respectively (data not shown). This may explain the sudden lesions, as ulcerative 
dermatitis is described for FeLV-infection in some cases (80). A possible protein loss 
over the intestines may have been responsible for very low protein concentration loss 
and development of edema, a pattern associated with FeLV-related diseases such as 
an intestinal lymphoma. Interestingly, although intestines, liver and kidneys were 
carefully examined for presence of lymphoma, no evidence of neoplasia was found. 
Thus, the etiology of the extremely low plasma protein concentration was not 
elucidated. 
Cat P2 showed signs of contact with FHV1 (PCR positive in week 1p.i. and seropositive 
afterwards) and FCV antigen (seropositivity), revealing that these two pathogens had 
been present in the lynx blood in quantities below the detection limit. Nevertheless, 
these subclinical infections, introduced through lynx blood inoculation, did not influence 
the outcome of FeLV infection, since this cat was progressing towards a regressive 
infection. The course of CMhm infection in group 1 was significantly different from group 
2, despite of the nearly identical loads in the blood utilized for infection. A possible 
explanation may be a difference in CMhm viability: while real-time PCR assays provides 
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reliable quantification of CMhm in blood samples (62) the true correlation between copy 
number and the number of living organisms would require quantitative culture which is 
not yet possible (81). A higher infectivity of the inocula and/ or intraperitoneal (obligatory 
because of the experimental infection with FeLV) rather than intravenous administration 
may explain the differences with already described courses of CMhm infection, where 
the loads peaked in weeks 2 to 4 (82, 83). Alternatively, the different infection course of 
CMhm may have been influenced by FeLV infection outcome itself, but this was not 
testable in the experimental setting that was used. Although a relationship between 
retroviruses (e.g., FeLV or FIV) and hemotropic mycoplasmas co-infection has been 
postulated by different authors (35, 83-85), recent field studies did not find any 
association (50, 51). The results presented support the latter findings and show that a 
retrovirus-positive status with CMhm co-infection will not become manifest in a 
particular progression or outcome of disease on a short term. 
The low pathogenicity of the transmitted FeLV strain in SPF cats underscores the 
importance of alterations in host-related factors that together with environmental 
changes may all interact to affect the susceptibility of Iberian lynxes to disease (53). For 
example, the lack of endogenous FeLV-related sequences (6) might also contribute to a 
higher pathogenicity of FeLV infection in the Iberian lynxes, since a protective role of 
endogenously expressed retroviruses has been postulated e.g., for gammaretroviruses 
in mice (86-89). The lack of exposure to pathogens (e.g. FeLV, FIV, canine distemper 
virus (CDV)) might have made the Iberian lynx vulnerable to outbreaks of these 
diseases (44). Nevertheless, the most important factor may be the loss of genetic 
diversity as a consequence of inbreeding (especially in Doñana region), which ended up 
in the apparent lack of acquired immunity and immunocompetence of the Iberian lynxes 
against infectious agents (5, 47, 90). A primary immune deficiency of the lynxes may 
have made this species more vulnerable to infectious diseases, a fact which should be 
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thoroughly investigated and which may pose a real threat to the future survival of this 
species. 
6. Conclusions 
In conclusion, the present study shows that the FeLV virus responsible for the outbreak 
in Iberian lynxes in 2006/ 2007 is apparently not extremely pathogenic when inoculated 
into SPF domestic cats. Hence, we assume that there is no increased risk in case of 
lynx-to-cat retransmission. 
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